| 2.03 -0.015 (-0.73%) | 09-16 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.75 | 1-year : | 3.13 |
| Resists | First : | 2.36 | Second : | 2.68 |
| Pivot price | 2.03  |
|||
| Supports | First : | 1.85 | Second : | 1.53 |
| MAs | MA(5) : | 2.01  |
MA(20) : | 2.03 |
| MA(100) : | 2.65 |
MA(250) : | 0 | |
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 52.8 |
D(3) : | 51.9 |
| RSI | RSI(14): 46.4 |
|||
| 52-week | High : | 33.9 | Low : | 1.85 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ PLYX ] has closed above bottom band by 48.9%. Bollinger Bands are 87.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for {EMPTY} bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 2.16 - 2.17 | 2.17 - 2.18 |
| Low: | 2 - 2.01 | 2.01 - 2.02 |
| Close: | 2.01 - 2.03 | 2.03 - 2.05 |
Polaryx Therapeutics, Inc. functions as a biotechnology firm dedicated to advancing small-molecule therapies for lysosomal storage and neurodegenerative conditions. Its developmental pipeline includes a trio of promising candidates: PLX-100, which combines PLX-200 with an ancillary supplement, targeting late infantile neuronal ceroid lipofuscinosis (LINCL) and related forms of NCL. PLX-200, a repurposed compound already utilized to address various diseases in both adult and pediatric populations. And PLX-300, derived from an edible plant, which works by activating PPARa to enhance the production of transcription factor EB. The company, established in 2014, maintains its base of operations in Paramus, New Jersey.
Fri, 11 Sep 2026
Polaryx Therapeutics (PLYX) investors back board picks and 2026 auditor - Stock Titan
Sun, 06 Sep 2026
Polaryx Therapeutics (PLYX) Stock Analysis Report | Financials & Insights - Benzinga España
Wed, 22 Jul 2026
Polaryx Therapeutics, Inc. Files Form 8-K as Emerging Growth Company on NASDAQ (PLYX) – July 2026 - Minichart
Tue, 21 Jul 2026
Polaryx Therapeutics, Inc. Common Stock (NASDAQ: PLYX) Stock Price, News & Analysis - kalkine.ca
Wed, 11 Feb 2026
Polaryx Therapeutics, Inc. Common Stock (PLYX) Stock Live Price, Chart & News - CoinCodex
Mon, 02 Feb 2026
PLYX IPO News - Micro-cap Polaryx Therapeutics to trade on the Nasdaq today via direct listing - renaissancecapital.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 50 (M) |
| Shares Float | 7 (M) |
| Held by Insiders | 69.9 (%) |
| Held by Institutions | 4.4 (%) |
| Shares Short | 249 (K) |
| Shares Short P.Month | 307 (K) |
| EPS | -0.15 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.6 % |
| Return on Equity (ttm) | -96.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -6 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -14.5 |
| PEG Ratio | 0 |
| Price to Book value | 9.22 |
| Price to Sales | 0 |
| Price to Cash Flow | -17.42 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|